Time filter

Source Type

Ivry-sur-Seine, France

Carod J.-F.,Institute Pasteur Of Madagascar | Randrianarison M.,Center Hospitalier Soavinandriana | Razafimahefa J.,Service de Neurologie | Ramahefarisoa R.M.,Institute Pasteur Of Madagascar | And 6 more authors.
Diagnostic Microbiology and Infectious Disease | Year: 2012

This study aimed to evaluate 5 enzyme immunoassays for detecting human antibodies against Taenia solium in human serum and for the diagnosis of neurocysticercosis (NCC): DRG RIDASCREEN, NOVATECH, CYPRESS, and IVD A collection of 114 reference serum samples were used. All sera were tested both by ELISA and by an immunoblot method (enzyme-linked immunoelectrotransfer blot [EITB]). When compared with EITB, the Ridascreentest had the best positive concordance rate (85.1-91.2%) and the NovaLisa test showed the optimal negative concordance rate (93.7-95.6%). All tests had a sensitivity under 72% and a specificity above 60%. The best sensitivity was obtained using Ridascreen test (71.4%). An optimal specificity was achieved by the NovaLisa test. T. solium-positive sera all cross-reacted with E. granulosus positive samples. In the commercial assays evaluated here, the most appropriate ELISA test for screening may be the Ridascreen assay. Antibody detection seems to be not appropriate for NCC diagnosis because of its overall lack of sensitivity. © 2012 Elsevier Inc.

Vitamin K antagonists (VKA) and heparins are the commonly used therapeutics in the prevention of venous and arterial thromboembolic episodes. They have numerous advantages and few flaws: iatrogenicity and compulsory biological monitoring for the VKA, and activity limited to the parenteral way for heparins. Three new oral anticoagulants, direct inhibitors of factor Xa (Rivaroxaban, Apixaban) or of factor IIa or thrombin (Dabigatran Etexilate), do not need coagulation monitoring. The diet does not influence the activity of these 3 new molecules. A small number of drugs can modify their anticoagulant activity. The thromboprophylaxis in major orthopedic surgery and the non valvular atrial fibrillation are registered by the Health Authorities. Their use in the treatment of venous thromboembolic episodes and the prevention of recurrence or secondary prevention has not been yet validated by the Health Authorities. The physician's information and the patient's education are strongly recommended for the success of this therapeutic revolution. © 2011 Springer Verlag France.

Joly P.,Unite de Pathologie Moleculaire du Globule Rouge | Lacan P.,Unite de Pathologie Moleculaire du Globule Rouge | Garcia C.,Unite de Pathologie Moleculaire du Globule Rouge | Desbree A.,Jean Monnet University | And 2 more authors.
Hemoglobin | Year: 2013

We report two new variants of the δ-globin gene: Hb A2-Saint-Etienne [δ14(A11)Leu→Pro] and Hb A2-Marseille [δ22(B4)Ala→Lys]. The first variant has a low rate of expression, the second results from a double nucleotide mutation on the same codon. © 2013 Informa Healthcare USA, Inc.

Joly P.,Laboratoire Of Biochimie Et Of Biologie Moleculaire | Garcia C.,Laboratoire Of Biochimie Et Of Biologie Moleculaire | Lacan P.,Laboratoire Of Biochimie Et Of Biologie Moleculaire | Couprie N.,Laboratoire Biomnis | Francina A.,Laboratoire Of Biochimie Et Of Biologie Moleculaire
Hemoglobin | Year: 2011

We report two new hemoglobin (Hb) variants; one causing an impairment of the N-terminal glycation of the β-globin chain and the other a hematological phenotype of α-thalassemia (α-thal). The first variant is Hb Aix-les-Bains [β5(A2)Pro→Leu] and the second Hb Dubai [α122(H5)His→Leu (α2)]. These two new Hb variants were detected by chromatographic and electrophoretic methods and characterized by molecular studies. Hb Dubai gives an α-thalassemic phenotype and should be routinely detected for preventing severe Hb H disease in couples at-risk for α-thal. © 2011 Informa Healthcare USA, Inc.

Servant-Delmas A.,Sanguine | Mercier-Darty M.,Sanguine | Ly T.D.,Laboratoire Biomnis | Wind F.,CEA DAM Ile-de-France | And 3 more authors.
Journal of Clinical Virology | Year: 2012

Background: Natural variation and mutations in the envelope protein (S) of hepatitis B virus can translate into HBsAg variants no longer detectable by conventional HBsAg assays. Objectives: The aim of the study was to assess the performance of 13 commercial assays currently used for screening and clinical analysis of HBsAg variants. Study design: The limit of detection (LOD) for each assay was established using two reference standards (WHO HBsAg 00/588 and the SFTS French reference). Sensitivity was evaluated using different panels. Panel 1 included 25 recombinant HBs variants at three concentrations, panels 2 and 4 included 8 recombinant HBsAg variants and 9 wild-type proteins (genotypes A-F), respectively, panel 3 included 16 natural HBsAg variants. Results: LODs ranged from 0.011 to 0.095. IU/ml with the WHO standard, and from 0.021 to 0.326. ng/ml with the French reference. The overall percentage of positive signals using HBsAg variants ranged from 62.9% to 97.9%. Three substitutions: T123, D144A and G145, were negative at all concentrations with at least one assay. Discussion: Our findings show that, although they fulfil CE requirements for analytical sensitivity (LODs below 0.13. IU/ml), HBsAg assays may vary in their capacity to detect HBsAg variants. This limit in diagnosis performance should encourage the health regulatory agencies to include HBsAg variant panels in the evaluation process. © 2012 Elsevier B.V.

Discover hidden collaborations